Evidence map›Paper›PMID 40361516›Full record

ArticleCancers2025

The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.

Harun Muğlu, Kaan Helvacı, Bahadır Köylü, Mehmet Haluk Yücel, Özde Melisa Celayir, Umut Demirci, Başak Oyan Uluç, Gül Başaran, Taner Korkmaz, Fatih Selçukbiricik and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Harun MuğluMedical Oncology Department, Faculty of Medicine, İstanbul Medipol University, Istanbul 34810, Türkiye.ORCID 0000-0001-9584-0827
Kaan HelvacıMedical Oncology Department, Faculty of Medicine, Yüksek İhtisas University, Ankara 06520, Türkiye.ORCID 0000-0002-8394-8168
Bahadır KöylüMedical Oncology Department, Faculty of Medicine, Koç University, Istanbul 34010, Türkiye.ORCID 0000-0002-4462-6393
Mehmet Haluk YücelMedical Oncology Department, Faculty of Medicine, İstanbul Medipol University, Istanbul 34810, Türkiye.ORCID 0000-0001-6880-7204
Özde Melisa CelayirMedical Oncology Department, Faculty of Medicine, Acıbadem University, Istanbul 34752, Türkiye.ORCID 0000-0002-8562-7085
Umut DemirciMedical Oncology Department, Memorial Ankara Hospital, Ankara 06520, Türkiye.
Başak Oyan UluçMedical Oncology Department, Faculty of Medicine, Acıbadem University, Istanbul 34752, Türkiye.ORCID 0000-0002-6623-6273
Gül BaşaranMedical Oncology Department, Faculty of Medicine, Acıbadem University, Istanbul 34752, Türkiye.
Taner KorkmazMedical Oncology Department, Faculty of Medicine, Acıbadem University, Istanbul 34752, Türkiye.
Fatih SelçukbiricikMedical Oncology Department, Faculty of Medicine, Koç University, Istanbul 34010, Türkiye.
Ömer Fatih ÖlmezMedical Oncology Department, Faculty of Medicine, İstanbul Medipol University, Istanbul 34810, Türkiye.ORCID 0000-0001-7934-7039
Ahmet BiliciMedical Oncology Department, Faculty of Medicine, İstanbul Medipol University, Istanbul 34810, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibody–drug conjugatehormone receptor-positive breast cancermetastatic breast cancerreal-world datasacituzumab govitecantriple-negative breast cancerTrop-2

Identifiers

PMID40361516
PMCPMC12071266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.